Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$43 Mln
P/E Ratio
--
P/B Ratio
0.23
Industry P/E
--
Debt to Equity
0.09
ROE
-0.66 %
ROCE
-59.31 %
Div. Yield
0 %
Book Value
2.09
EPS
-1.31
CFO
$-277.98 Mln
EBITDA
$-147.01 Mln
Net Profit
$-400.44 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Adicet Bio (ACET)
| -40.91 | -25.63 | -37.43 | -70.85 | -66.66 | -41.65 | -- |
|
BSE Sensex*
| 1.77 | 3.54 | 5.00 | 8.95 | 11.20 | 21.05 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Adicet Bio (ACET)
| -48.82 | -78.86 | -48.89 | 24.48 | 34.71 | -82.71 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.59 | 9,973.38 | 20.56 | 23.13 | |
| 288.99 | 8,956.07 | 23.48 | 58.42 | |
| 25.13 | 9,559.25 | -- | -28.77 | |
| 100.68 | 10,030.35 | 30.81 | 14.16 |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors... (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts. Address: 131 Dartmouth Street, Boston, MA, United States, 02116 Read more
CEO, President & Director
Mr. Chen Schor BA, CPA, M.B.A.
CEO, President & Director
Mr. Chen Schor BA, C.P.A., M.B.A.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Adicet Bio Inc (ACET) stood at $ 220 Mln as on 31-Dec-24
The share price of Adicet Bio Inc (ACET) is $0.57 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Adicet Bio Inc (ACET) has given a return of -66.66% in the last 3 years.
Adicet Bio Inc (ACET) has a market capitalisation of $ 43 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Adicet Bio Inc (ACET) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Adicet Bio Inc (ACET) and enter the required number of quantities and click on buy to purchase the shares of Adicet Bio Inc (ACET).
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts. Address: 131 Dartmouth Street, Boston, MA, United States, 02116
The CEO & director of Mr. Chen Schor BA, CPA, M.B.A.. is Adicet Bio Inc (ACET), and CFO & Sr. VP is Mr. Chen Schor BA, C.P.A., M.B.A..
There is no promoter pledging in Adicet Bio Inc (ACET).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Adicet Bio Inc. (ACET) | Ratios |
|---|---|
|
Return on equity(%)
|
-65.65
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Adicet Bio Inc (ACET) was $0 Mln.
$0.04
(
